Preventing chronic ectopic bone-related pain and disability after hip replacement surgery with perioperative ibuprofen. A multicenter, randomized, double-blind, placebo-controlled trial (HIPAID)

Controlled Clinical Trials

Volumn 25, Issue 2, 2004, Pages 223-233

  Fransen, Marlene ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Disability; Ectopic bone; Hip replacement; NSAIDs; Placebo controlled; Randomized

Indexed keywords

IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ARTICLE; BLEEDING; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; DOUBLE BLIND PROCEDURE; ELECTIVE SURGERY; GASTROINTESTINAL DISEASE; HIP DISEASE; MULTICENTER STUDY; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PHYSICAL PERFORMANCE; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THEORETICAL MODEL; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; CHRONIC DISEASE; HUMANS; IBUPROFEN; MULTICENTER STUDIES; NEW ZEALAND; OSSIFICATION, HETEROTOPIC; PAIN; PERIOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 1542380996     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2003.11.008     Document Type: Article

References (37)

1. Gogia P., Christensen C., Schmidt C. Total hip replacement in patients with osteoarthritis of the hip: improvement in pain and functional status. Orthopaedics. 17:1994;145-150.
2. Kay A., Davison B., Badley E., Wagstaff S. Hip arthroplasty: patient satisfaction. Br. J. Rheumatol. 22:1983;243-249.
3. Patterson A. The McKee Farrar total hip replacement. Preliminary results and complications of 368 operations performed in five general hospitals. J. Bone Joint Surg. 54-A:1972;257-275.
4. Neal B. Hip surgery and heterotopic bone formation. Medicine. 1999;Auckland, Auckland.
5. Givon U., Ginsberg G.M., Horoszowski H., Shemer J. Cost-utility analysis of total hip arthroplasties. Technology assessment of surgical procedures by mailed questionnaires. Int. J. Technol. Assess. Health Care. 14:1998;735-742.
6. Imamura K., Black N. Outcome of total hip replacement in Japan and England. Comparison of two retrospective cohorts. Int. J. Technol. Assess. Health Care. 14:1998;762-773.
7. Lieberman J.R., Dorey F., Shekelle P.et al. Differences between patients' and physicians' evaluations of outcome after total hip arthroplasty. J. Bone Joint Surg. 78-A:1996;835-838.
8. Brooker A., Bowerman J., Robinson R., Riley L. Ectopic ossification following total hip replacement. J. Bone Joint Surg. 55-A:1973;1629-1632.
9. Neal B., Gray H., MacMahon S., Dunn L. Incidence of heterotopic bone formation after major hip surgery. ANZ. J. Surg. 72:2002;808-821.
10. Neal B., Rodgers A., Gray H.et al. No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement. A randomised trial of 2,649 patients. Acta Orthop. Scand. 71:2000;129-134.
11. Neal B.C., Rodgers A., Clark T.et al. A systematic overview of 13 randomised trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop. Scand. 71:2000;122-128.
12. Jupiter J. Heterotopic ossification at the elbow. Tullos H.D. Instructional course lectures. 1991;41-44 American Academy of Orthopaedic Surgeons, Illinois.
13. Sneath R.J.S., Bindi F.D., Davies J., Parnell E.J. The effect of pulsed irrigation on the incidence of heterotopic ossification after total hip arthroplasty. J. Arthroplasty. 16:2001;547-551.
14. Nilsson O.S., Persson P.-E. Heterotopic bone formation after joint replacement. Curr. Opin. Rheumatol. 11:1999;127-131.
15. Knelles D., Barthel T., Karrer A.et al. Prevention of heterotopic ossification after total hip replacement: a prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J. Bone Joint Surg. 79-B:1997;596-602.
16. Henry D., Lim L., Garcia Rodriguez L.et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 312:1996;1563-1566.
17. Cashman J., McAnulty G. Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Drugs. 49:1995;51-70.
18. Brooks P.M., Day R.O. Non-steroidal antiinflammatory drugs - differences and similarities. N. Engl. J. Med. 324:1991;1716-1725.
19. Dahl J.B., Kehlet H. Non-steroidal anti-inflammatory drugs: rationale for use in severe postoperative pain. Br. J. Anaesth. 66:1991;703-712.
20. McMahon J.S., Waddell J.P., Morton J. Effect of short-course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J. Arthroplasty. 6:1991;259-264.
21. Wurnig C., Schwameis E., Bitzan P., Kainberger F. Six-year results of a cementless stem with prophylaxis against heterotopic bone. Clin. Orthop. 361:1999;150-158.
22. Kristensen S.S., Pedersen P., Pedersen N.W.et al. Combined treatment with indomethacin and low-dose heparin after total hip replacement. J. Bone Joint Surg. 72-B:1990;447-449.
23. Persson P.-E., Sodemann B., Nilsson O.S. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. Acta Orthop. Scand. 69:1998;111-115.
24. Horlocker T.T., Wedel D.J. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic. Anesth. Analg. 86:1998;1153-1155.
25. Elmstedt E., Lindholm T.S., Nilsson O.S., Tornkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop. Scand. 56:1985;25-27.
26. Day R., Morrison B., Luza A.et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Arch. Intern. Med. 160:2000;1781-1787.
27. Cronberg S., Wallmark E., Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand. J. Haematol. 33:1984;155-159.
28. Connelly C.S., Panush R.S. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch. Intern. Med. 151:1991;1963-1966.
29. Bellamy N., Buchanan W.W., Goldsmith C.H.et al. Validation study of WOMAC: a health status instrument for measuring clinically-important patient - relevant outcomes following total hip or knee arthroplasty in osteoarthritis. J. Orthop. Rheumatol. 1:1988;95-108.
30. Jenkinson C., Stewart-Brown S., Petersen S., Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J. Epidemiol. Community Health. 53:1999;46-50.
31. Ware J., Snow K., Kosinski M.et al. SF-36 health survey: manual and interpretation guide. 1993;The Health Institute, New England Medical Center, Boston, MA.
32. Bellamy N., Kirwan J., Boers M.et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J. Rheumatol. 24:1997;799-802.
33. Bryant M.J., Kernohan W.G., Nixon J.R., Mollan R.A. A statistical analysis of hip scores. J. Bone Joint Surg. 75-B:1993;705-709.
34. Podsiadlo D., Richardson S. The timed "up and go": a test of basic functional mobility for frail elderly persons. J. Am. Geriatr. Soc. 39:1991;142-148.
35. Australian Bureau of Statistics National health survey. SF-36 population norms. 1997;ACT, Belconnen.
36. Woodward M. Epidemiology. Study design and data analysis. 1999;Chapman & Hall/CRC, Boca Raton.
37. Schafer J.L. Analysis of incomplete multivariate data. 1997;Chapman & Hall, London.